

Ref: GLL/BSE/2022/July-02

Date: July 16, 2022

To  
Corporate Relations Manager  
BSE Limited  
Phiroje Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001

To  
Listing Manager  
The Ahmedabad Stock Exchange Limited  
A-2, Kamdhenu Complex,  
Opposite Sahajanand College,  
120 Feet Ring Rd, Panjara Pol, Ambawadi,  
Ahmedabad – 380 015

To  
The Secretary  
The Calcutta Stock Exchange Limited  
#7, Lyons Range, Murgighata,  
Dalhousie, Kolkata – 700 001

**Sub:** Outcome of the Meeting of Board of Directors of Gennex Laboratories Limited - Scrip Code: 531739/GENNEX

**Ref:** Regulation 30 & 42 of the SEBI (LODR) Regulations, 2015.

Dear Sir/Ma'am,

With reference to the Captioned subject matter and pursuant Reg.30 of SEBI(LODR) Regulations, 2015, This is to inform you that the Board of Directors in their meeting held Friday, June 24, 2022, i.e., Today has considered and approved, inter-alia the following Business items:

1. Approved the issue of 6,32,51,500 Rights Equity Shares of face value on ₹1/- each at an issue price on ₹6/- per Rights Equity Share (including premium of ₹5/- per Rights Equity Share) for an amount aggregating up to ₹37.951 Crores to all the existing equity shareholders of the Company on a rights basis ("Rights Issue"), subject to requisite approvals from the statutory, regulatory and other authorities, as applicable. The brief terms of the Rights Issue approved by the Board of Directors of the Company is annexed herewith marked as **Annexure I**.
2. Fixed the record date i.e. Friday, July 22, 2022 for the purpose of determining names of shareholders of the Company eligible to apply for the partly paid-up Rights Equity Shares in the Rights Issue of the Company.
3. Schedule of the Rights Issue:

Issue Opening Day & Date	Friday, August 05, 2022
Last date for on Market Renunciation of the Rights Entitlements*	Friday, August 12, 2022
Issue Closing Day & Date#	Friday, August 19, 2022



## Gennex Laboratories Limited

Office : 'Akash Ganga' 3rd Floor, Plot No.144, Srinagar Colony, Hyderabad-500073, T.S, India | Phone : +91-40-67334400 (30 Lines), Fax : +91-40-67334433  
Factory : Sy. No. 133, IDA Bollaram, Jinnaram Mandal, Sangareddy Dist - 502 325. Telangana, India | Tel : +91-08458 279406, Telefax : +91-08458 279516

info@gennexlab.com, www.gennexlab.com ■ CIN : L24230TG1990PLCO11168

*\*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncees on or prior to the Issue Closing Date.*

*#Our Board or a duly authorized committee thereof will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the issue Opening Date (inclusive of the issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.*

4. The Company has been allotted the International Securities Identification Number (ISIN) for the purpose of credit of rights entitlements. The ISIN of the Rights Entitlements is **INE509C20018**. The Rights Entitlements of Eligible Equity Shareholders as on record date shall be credited, prior to the issue opening date, in their respective demat accounts under the aforementioned ISIN.
5. Adoption of Letter of Offer and Abridged Letter of Offer to be filed with BSE Limited, and the Securities and Exchange Board of India and will be dispatched to the Eligible Equity Shareholders of the Company as on the Record Date in due course.

The Board Meeting commenced at 15:00 Hrs and Concluded at 15:35Hrs.



This intimation is also uploaded in the Company website: [www.gennexlab.com](http://www.gennexlab.com).

We request you to take note of the above information on record and acknowledge the receipt of the same.

Thanking you,

Yours Truly,

**For Gennex Laboratories Limited**



**Rajesh Vankadara**  
Company Secretary & Compliance Officer  
Membership #A44949

## Details of the Rights Issue

#	Particulars	Details			
1	Type of Securities proposed to be issued	Partly Paid-up Equity shares of face value on ₹1/- each ("Rights Equity Shares").			
2	Type of Issuance	Rights Issue of partly paid-up Equity Shares.			
3	Total Number of Securities to be issued	6,32,51,500 Rights Equity Shares of face value on ₹1/- each at an issue price on ₹6/- per Rights Equity Share for an amount aggregating up to ₹37.951 Crores *assuming full subscription			
4	Issue Price	₹6/- per Rights Equity Share (including premium of ₹5/- per Rights Equity Share)			
5	Term of the Payment	<b>Schedule</b>	<b>Face Value (₹)</b>	<b>Premium (₹)</b>	<b>Total (₹)</b>
		On Application (in ₹)	0.25	1.25	1.50
		On First and Final Call (in ₹)	0.75	3.75	4.50
		<b>Total (₹)</b>	1.00	5.00	6.00
6	Record Date	Friday, July 22, 2022			
7	ISIN for Rights Entitlement	INE509C20018			
8	Rights Entitlement Ratio	1 (One) Rights Equity Share of ₹1/- each for Every 2 (Two) Fully Paid-Up Equity Shares ₹1/- each held by the Existing Equity Shareholders as on the Record Date ("Eligible Equity shareholders") with the Right to renounce.			
9	Outstanding Equity shares prior to the Rights Issue	12,65,03,000 Equity Shares of ₹1/- each			
10	Outstanding Equity shares post to the Rights Issue (assuming Full subscription)	18,97,54,500 Equity Shares of ₹1/- each			

The detailed terms of the Rights Issue including the procedure for applying in the Rights Issue and fractional entitlements will be specified in the Letter of Offer which will be filed by the Company with Securities and Exchange Board of India, BSE Limited in due course.

For Gennex Laboratories Limited

  
  
**Rajesh Vankadara**  
 Company Secretary & Compliance Officer  
 Membership #A44949